Gastrointestinal Stromal Tumor (GIST)

Adult trials (Ages 18 and older)

Interventional trials

All Mutation Types (KIT, PDGFRA D842V, Wild)

2nd Line Only

3rd or 4th Line

All Mutation Types (except KIT occurring with PDGFRA-Wild)

2nd Line and Beyond

KIT and PDGFRA (D842V) Mutations

PDGFRA D842V Only

2nd or 3rd Line

SDH-Mutant/deficient GIST

2nd Line Only

3rd or 4th Line

IRB #19262
A Phase 3, Interventional, Randomized, Multicenter, Open-label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)

IRB # 22722
A Phase 1, Multi-center, Open-label Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2CB Probe Substrate (Regaplinide) in Patients with Advanced GIST

IRB # 22777
A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midozolam in Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors.

IRB # 23182
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

IRB #17155
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

IRB # 21229
Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Subjects with Advanced Gastrointestinal Stromal Tumor

IRB #21884
An Open-Label, Phase 2 Efficacy Study of Temozolomide in Advanced SDH Mutant/Deficient GIST

CROSS-DISEASE TRIALS:

IRB# 19992
EAY131 (MATCH)

IRB# 18084
S1609 (DART)

http://www.ohsu.edu/research/rda/sjso/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

18NOV2021